|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current Assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts and notes receivable-trade, net | ||||||||||||||||||||
| Inventories, net | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Property, plant, and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets, net | ||||||||||||||||||||
| Identifiable intangible assets, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other noncurrent assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| Liabilities and Equity | ||||||||||||||||||||
| Current Liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued liabilities | ||||||||||||||||||||
| Income taxes payable | ||||||||||||||||||||
| Notes payable and current portion of long-term debt | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Deferred income taxes | ||||||||||||||||||||
| Other noncurrent liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Equity: | ||||||||||||||||||||
| Preferred stock, $1.00 par value; 0.25 million shares authorized; no shares issued | ||||||||||||||||||||
| Common stock, $0.01 par value; 400.0 million shares authorized, and 264.5 million shares issued at June 30, 2026 and December 31, 2025 200.3 million and 199.6 million shares outstanding at June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Capital in excess of par value | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Treasury stock, at cost, 65.3 million and 64.9 million shares at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Total Dentsply Sirona Equity | ||||||||||||||||||||
| Noncontrolling interests | ||||||||||||||||||||
| Total Equity | ||||||||||||||||||||
| Total Liabilities and Equity | ||||||||||||||||||||
Loading...
